Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
941-960 of 1,738 trials

Colon Cancer: Neoadjuvant Dostarlimab Treatment

We are studying the effects of Dostarlimab in patients with untreated Stage III colon cancer. This trial aims to understand how well the treatment works and its safety before surgery.

Resectable Colon Cancer≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterologyOncology

Triple-Negative Breast Cancer: NECVAX-NEO1 Treatment

We are studying the safety and effects of NECVAX-NEO1 added to standard PD-1 inhibitor therapy for patients with triple-negative breast cancer. This trial aims to see if the new treatment can enhance cancer response and improve outcomes.

Triple Negative Breast Cancer6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Muscle-Invasive Bladder Cancer: Erdafitinib Treatment Study

We are studying the effects of erdafitinib alone and with cetrelimab in patients with muscle-invasive bladder cancer who cannot take cisplatin. The goal is to see if this treatment can shrink tumors before surgery.

Muscle-Invasive Bladder Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncologyUrology

Gene Therapy for Hearing Loss: AAVAnc80-hOTOF

We are studying a new gene therapy for people with hearing loss due to Otoferlin gene mutations. The trial aims to assess the long-term safety and effectiveness of this treatment.

Otoferlin Gene-Mediated Hearing Loss>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesInternal MedicineNeurologyOtolaryngology

Azithromycin for Hospitalized Children with Asthma Symptoms

We are studying whether a three-day treatment with azithromycin helps young children aged 1-5 years who are hospitalized due to asthma-like symptoms. This research may lead to better, personalized treatments based on individual responses.

Childhood Asthma>2 yearsEfficacy phase (II)Investigational MedicinesPediatricsPulmonology

Advanced Solid Tumors: Repotrectinib Study

We are testing a new treatment called repotrectinib for patients with advanced solid tumors that have specific genetic changes. The study aims to evaluate its safety and effectiveness in improving tumor response.

Advanced Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Primary Aldosteronism: New Imaging Technique Study

We are comparing a new PET/CT imaging method with a standard test to see which better identifies adrenal tumors in patients with primary aldosteronism. This may help improve treatment for hypertension linked to this condition.

Primary Hyperaldosteronism1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology

Endometrial Stromal Sarcoma: Aromatase Inhibitor Treatment Study

We are comparing the effects of stopping versus continuing aromatase inhibitors in patients with advanced low-grade endometrial stromal sarcoma. This study aims to find out which approach may help patients live longer without disease progression.

Low-Grade Endometrial Stroma Sarcoma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Gastrointestinal Stromal Tumors: Imatinib Treatment Study

We are exploring whether continuing or stopping imatinib treatment after 10 years benefits patients with advanced GISTs. The study looks at health outcomes like survival rates and quality of life.

Locally Advanced or Metastatic Gastrointestinal Stromal Tumors>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

X-Linked Hypohidrotic Ectodermal Dysplasia: ER004 Treatment

We are studying a new prenatal treatment for male infants with X-linked hypohidrotic ectodermal dysplasia to see if it improves sweating ability and dental health. The trial also examines the safety of this treatment for both the infants and their mothers.

X-linked Hypohidrotic Ectodermal Dysplasia≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal MedicinePediatrics

Crohn's Disease: SAR441566 Treatment Study

We are investigating how different doses of SAR441566 affect symptoms and health in adults with moderate to severe Crohn's disease. This study aims to find out if the medication can help improve patients' quality of life and overall condition.

Crohn's Disease1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Mantle Cell Lymphoma: Ibrutinib and Venetoclax Study

We are studying the effects of Ibrutinib alone and in combination with Venetoclax in patients with untreated mantle cell lymphoma. The goal is to see how well these treatments reduce disease levels in the body.

Untreated Mantle Cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Infectious Pulmonary Endotheliopathy: Iloprost Infusion Study

We are investigating whether a continuous infusion of iloprost can help reduce the risk of death in mechanically ventilated patients with infectious pulmonary issues. This study compares the treatment to a placebo to assess its effectiveness.

Respiratory FailureInfectious Pulmonary Endotheliopathy>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Stem Cell Transplant for Children with Acute Lymphoblastic Leukemia

We are studying different conditioning treatments for children and adolescents with acute lymphoblastic leukemia undergoing stem cell transplantation. Our goal is to find out which treatment leads to better survival and fewer side effects.

Acute Lymphoblastic Leukaemia1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesHematologyOncologyPediatrics

Cardio Renal Syndrome: Peritoneal Ultrafiltration Treatment

We are studying whether Peritoneal Ultrafiltration can help prevent heart failure worsening in patients with Cardio Renal Syndrome. The trial also looks at improvements in health and quality of life.

Congestive Heart Failure>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyInternal MedicineNephrology

Advanced Melanoma: EIK1001 and Pembrolizumab Study

We are studying a new treatment combining EIK1001 with pembrolizumab for patients with advanced melanoma. The goal is to see if this combination improves survival and slows disease progression compared to a placebo.

Advanced Melanoma1-2 yearsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesPartially RemoteOncology

Wiskott-Aldrich Syndrome: Gene Therapy Follow-Up

We are monitoring the long-term safety of a gene therapy in patients with Wiskott-Aldrich Syndrome who received a specific stem cell treatment. This study helps us understand how the therapy affects their health over time.

Wiskott-Aldrich Syndrome>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematology

BCR-ABL1+ Chronic Myeloid Leukemia: Asciminib Treatment Study

We are studying Asciminib, alone or with Nilotinib, for adults with BCR-ABL1+ Chronic Myeloid Leukemia. The goal is to see if this treatment helps achieve better disease control and improves quality of life.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Systemic Juvenile Idiopathic Arthritis: Sarilumab Study

We are testing the medication sarilumab in children and adolescents with systemic juvenile idiopathic arthritis to find the best dose and understand its effects and safety.

Systemic Juvenile Idiopathic Arthritis (sJIA)3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Relapsing Multiple Sclerosis: Obexelimab Study

We are testing a new medication, Obexelimab, to see if it helps prevent new brain lesions in people with relapsing multiple sclerosis. The study will also assess the safety of this treatment compared to a placebo.

Relapsing-Remitting Multiple Sclerosis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineNeurology